Αποτελέσματα Αναζήτησης
Well, it happened again that the first word came from the financial community (report here), as we learned today that a large trial testing the value of maintenance tarceva (erlotinib), the oral EGFR inhibitor, provides a significant improvement in progression-free survival (PFS).
21 Αυγ 2009 · According to data from the Sequential Tarceva in Unresectable NSCLC (SATURN) trial, which was presented at the 13th World Conference on Lung Cancer, maintenance therapy with erlotinib improved overall survival in patients with advanced NSCLC after initially successful chemotherapy.
Shortly after ASCO 2009, Dr. Pennell provided the highlights of the early report of the SATURN trial, conducted primarily in Europe, that randomized patients to maintenance tarceva (erlotinib) or placebo after four cycles of first line chemotherapy.
22 Οκτ 2024 · Robust EGFR or Her2 inhibitors, like Tarceva and Tratusamab, prevent this signaling cascade and turn CDK2/4/6 off, preventing proliferation. But the field has long recognized that another way to prevent the signaling from overactive receptors or constitutive cytoplasmic proteins is to “drug” CDK2/4/6 directly.
Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer. When prescribing Tarceva, factors associated with prolonged survival should be taken into account.
4 Αυγ 2009 · Top-line data from Tarceva's Phase III maintenance trial, dubbed SATURN, had investors worried that the drug might not be able to compete with Alimta. Progression-free survival was 12.3 weeks (3.07 months) for Tarceva vs. 11.1 weeks (2.78 months) for placebo (p < 0.0001, hazard ratio = 0.71).
8 Μαΐ 2019 · Tarceva (erlotinib) is widely used in the management of EGFR + non-small cell lung cancer (NSCLC) and clinical studies suggests it improves survival in early stage disease, as part of initial treatment for stage IV NSCLC, as maintenance therapy and in select individuals with recurrent disease.
